Biotechnology

3SBIO

Zhongtai Securities lowers Sanhome's earnings forecast and maintains Buy rating

CStone Pharmaceuticals Reaps Significant Benefits from 707 Authorization Deal with Pfizer

Morgan Stanley Downgrades CSB Pharmaceutical's Revenue and Earnings Forecast

DualityBio’s drug application accepted by China’s NMPA

BOC International Raises Target Price for Three Seasons Pharmaceutical

Sanke Biopharmaceutical Reports Significant Growth in 2025 Performance and Global Collaboration with Pfizer

3SBIO released FY2025 Q3 earnings on March 30, 2026 (BJT), with actual revenue of HKD 7.292 B and EPS of HKD 1.5587

3SBIO released FY2025 9 Months earnings on March 30, 2026 (BJT), with actual revenue of HKD 12.01 B and actual EPS of HKD 2.165

Sensing Pharma Reports Significant Profit Growth for FY2025 and Pushes Ahead with Mandi Spin-Off Plans

3SBIO released FY2025 earnings on March 30 After-Market (BJT), actual revenue HKD 19.34 B (forecast HKD 20.51 B), actual EPS HKD 3.7496 (forecast HKD 4.3571)

3SBIO released FY2025 Q4 earnings on March 30 After-Market (BJT), actual revenue HKD 7.417 B, actual EPS HKD 1.5856

3SBIO to Release FY2025 Earnings on March 30 After-Market (BJT), Forecast Revenue HKD 20.98 B, EPS HKD 4.4323

Rosera Erythropoietin Alpha Injection Approved for Market by Guangdong Sispharm

UBS Names CSPC Pharmaceutical Group as Top Pick in Healthcare Sector

CMB Analyst Reiterates Buy Rating for 3SBio with Target Price

Pfizer and Sino Legend Biopharmaceuticals Advance PD-1/VEGF Bispecific Antibody Development

Huitianfu Fund Management Co. Reduced ST Pharm to 1.7845 million shares

CITIC Fund Management Co., Ltd.增持三生制药

Sizhe Bio Completes $40 Million Financing to Advance iPSC-Derived Neural Cell Drug Development

China's Pharmaceutical Companies Achieve Record Foreign Licensing Deals in 2025

NTES-S

KWAN YONG

PEIJIA-B

REMEGEN

RADIANCE HLDGS

POP MART

BAOZUN-W

ARCHOSAUR GAMES

XIAOCAIYUAN

HEPALINK

01530

3SBio shareholders have approved a resolution to distribute all shares of subsidiary Mandi Inc. as a special dividend, with 99.995% support at an extraordinary general meeting on April 23, 2026. This move aims to advance the spin-off strategy and reshape the company's capital structure. The board has been granted authority to determine distribution mechanics, reflecting strong investor backing. The latest analyst rating for 3SBio (HK:1530) is a Hold with a price target of HK$29.43, and the company operates in the biopharmaceutical sector with a market cap of HK$62.99B.

Tip Ranks

Computershare Limited

Sunshine Guojian Pharmaceutical

3SBio Shareholders Back Spin-Off Dividend of Mandi Inc. Shares

00068

02655

02635

09926

01384

06651

02509

06051

02556

MANYCORE TECH(00068) fell 18.77%, with a trading turnover 1.1 Billion HKD, and a year-to-date rose 298.7%. GUOXIA TECH(02655) fell 15.31%, with a trading turnover 444.1 Million HKD, and a year-to-date fell 33%. NUOBIKAN(02635) fell 14.62%, with a trading turnover 148.7 Million HKD, and a year-to-date rose 4.3%.

Top Gainers&Losers

MANYCORE TECH

GUOXIA TECH

NUOBIKAN

AKESO

DEEPEXI TECH

51WORLD

QYUNS-B

YOUZAN

MARKETINGFORCE

Top 10 HK Stock Losers (4.23)

3SBIO fell 11.02%; CanSino Biologics fell 11.92%, with a transaction volume of HKD 1.754 billion; Innovent Biologics fell 5.05%, with a transaction volume of HKD 639 million; Rongchang Biologics fell 6.24%, with a transaction volume of HKD 302 million; BeiGene fell 0.80%, with a market value of HKD 285.3 billion

HK Stock Alerts

Hong Kong Stock Movement: 3SBIO fell 11.02%, as favorable policies and breakthroughs in AI technology failed to boost market confidence

02442

09606

02575

02225

02657

09995

00290

EASY SMART GP(02442) rose 21.49%, with a trading turnover 53.3 Million HKD, and a year-to-date rose 109.8%. 51WORLD(06651) rose 15.21%, with a trading turnover 1.8 Billion HKD, and a year-to-date rose 37.8%. DUALITYBIO-B(09606) rose 10.81%, with a trading turnover 488.5 Million HKD, and a year-to-date rose 6.6%.

EASY SMART GP

DUALITYBIO-B

XUANZHUBIO-B

JINHAI MED TECH

FOREST CABIN

GOFINTECH QUANT

Top 10 HK Stock Gainers (4.15)

159615

159506

520880

159316

520690

588860

159837

159102

159859

DualityBio announced that its new drug DB-1303 has been accepted for listing by the National Medical Products Administration. This drug targets HER2-positive unresectable or metastatic breast cancer patients, showing significant efficacy and good safety based on the results of Phase III clinical trials. DualityBio is collaborating with 3SBIO to promote the commercialization of DB-1303 in mainland China, Hong Kong, and Macau, and will continue to deepen its global strategic cooperation with BioNTech

Tasty Money

China Southern Hang Seng Biotech ETF(QDII)

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Penghua SSE STAR Biology and Medicine ETF

E Fund CSI 300 Health Care ETF

ChinaAMC CSI Biotechnology Theme ETF

E Fund Hang Seng SCHK Innovative Drug ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

Ping An CSI Medicine and Medical Device Innovation ETF

ICBCCS SSE STAR Biology and Medicine ETF

China Merchants CSI Biotechnology Theme ETF

Guotai CSI Bio-medicine ETF

E Fund CSI Biotechnology Theme ETF

Huaan Hang Seng Biotech ETF

Yinhua CSI Innovative Drugs Industry ETF

Minsheng Royal CSI Biotechnology Theme ETF

ChinaAMC SSE Health Care ETF Initiating Fund

GF CSI HK Innovative Drugs Industry ETF(QDII)

Tianhong CNI BIOMEDICINE ETF

Penghua CSI HK Connect Health Care Composite ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Bosera Hang Seng Health Care ETF(QDII)

DUALITYBIO's new drug application for adult breast cancer has been accepted by the National Medical Products Administration, promoting commercialization in mainland China, Hong Kong, and Macau

Morgan Stanley lowered the target price for 3SBIO to 34 yuan, with a rating of "Overweight." Due to the depreciation of the US dollar against the Chinese yuan, the sales forecast for 3SBIO's core product TPIAO and milestone payments have been revised downwards, resulting in revenue forecasts for 2026, 2027, and 2028 being lowered by 5%, 7%, and 6%, respectively. At the same time, product gross margin and operating expense ratio have also been adjusted, with expected earnings per share revised down by 8.3%, 14.5%, and 12.4%, respectively

AASTOCKS

First Trust NYSE Arca Biotech Index Fd

Morgan Stanley lowered the target price for 3SBIO to 34 yuan, rating it as "Overweight."

LABD

3SBio's profits surged due to a major licensing deal with Pfizer, with revenues rising 94% to $2.58 billion in 2025. However, core sales fell 9.3%, raising concerns among investors. The company faces competitive pressures on its established products, leading to market share erosion. Despite the financial boost from Pfizer, the decline in core income highlights challenges in sustaining growth. 3SBio's cash reserves stand at 12.18 billion yuan, with ongoing R&D efforts and new drug approvals, but investor sentiment remains mixed, reflected in stock price volatility.

- 3SBio reported a 94% revenue increase to $2.58 billion in 2025 due to over $1 billion in early payments from Pfizer for a cancer drug partnership.  
- Despite the revenue surge, income from core products fell by 9.3%, raising concerns about sustainability as established products face competitive pressures.  
- The company’s financial status has been bolstered by cash reserves of 12.18 billion yuan and R&D investments, though future success is contingent on recovering core sales and the outcomes of ongoing clinical trials.

benzinga_article

Direxion S&P Biotech Bear 3X

iShares US Pharma

VanEck Biotech ETF

iShares Global Healthcare

SPDR S&P Biotech

Ark Genomic Revolution ETF

Direxion S&P Biotech Bull 3X

iShares Biotechnology ETF

Proshares Ultra Nasdaq Biotech

VG Health

Invesco Biotechnology & Genome ETF

Hwabao WP CSI Pharmaceuticals ETF

Invesco Nasdaq Biotechnology ETF

Pfizer

Direxion Daily Biotech Top 5 Bull 2X ETF

ALPS Medical Breakthrough

Mega Licensing Deal Boosts 3SBio Profits But Core Sales Slip

02656

00568

03668

01921

02025

02632

06821

03378

01579

160 HEALTH(02656) fell 32.4%, with a trading turnover 126.5 Million HKD, and a year-to-date rose 22.9%. SHANDONG MOLONG(00568) fell 12.99%, with a trading turnover 1.2 Billion HKD, and a year-to-date rose 153.6%. YANCOAL AUS(03668) fell 8.4%, with a trading turnover 291.2 Million HKD, and a year-to-date rose 64.3%.

160 HEALTH

SHANDONG MOLONG

YANCOAL AUS

DALIPAL HLDG

RUIFENG POWER

NEW VISION CO

Asymchem

HANXBIO-B

YIHAI INTL

Top 10 HK Stock Losers (4.8)

In a report released yesterday, from Bank of China maintained a Buy rating on 3SBio, with a price target of HK$38.30.End of Quarter Sale - 50% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks In a report released yesterday, CMB International Securities also maintained a Buy rating on the stock with a HK$34.87 price target.

Bank of China Remains a Buy on 3SBio (TRSBF)

3SBIO(01530.HK)